ChongQingEnNaDianZiShangWuYouXianGongSi – Trademark Portfolio

Entity Type: 99

ChongQingEnNaDianZiShangWuYouXianGongSi holds 3 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 10 (Medical Apparatus) — 3 filings in this category. Currently, 3 trademarks are registered. Notable registered marks include XUX, SGOE, and CATTELAN. The owner is based in ChongQing.

Jiang Bei Qu Chun SenBi An Xiao Qu1 Hao

ChongQing 400000 , CN

3 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

SGOE
SGOE
Registered 2020
XUX
XUX
Registered 2020
CATTELAN
CATTELAN
Registered 2020

Trademark Classifications

ChongQingEnNaDianZiShangWuYouXianGongSi's trademark portfolio spans 1 Nice Classification class, reflecting the scope of goods and services protected under their brand portfolio.

10
Medical Apparatus (3 filings)

Surgical, medical, dental and veterinary apparatus and instruments

Frequently Asked Questions

How many trademarks does ChongQingEnNaDianZiShangWuYouXianGongSi have?

ChongQingEnNaDianZiShangWuYouXianGongSi has 3 U.S. trademarks filed with the USPTO. Of these, 3 registered.

What trademark classes does ChongQingEnNaDianZiShangWuYouXianGongSi file in?

ChongQingEnNaDianZiShangWuYouXianGongSi files trademarks across 1 Nice Classification class. The most active classes are Class 10 (Medical Apparatus). Class 10 covers surgical, medical, dental and veterinary apparatus and instruments.

What are ChongQingEnNaDianZiShangWuYouXianGongSi's most well-known trademarks?

ChongQingEnNaDianZiShangWuYouXianGongSi's registered trademark portfolio includes well-known marks such as XUX, SGOE, and CATTELAN. These are among 3 currently registered trademarks in the portfolio.

What is ChongQingEnNaDianZiShangWuYouXianGongSi's trademark registration success rate?

ChongQingEnNaDianZiShangWuYouXianGongSi has a 100% trademark registration rate, with 3 out of 3 resolved applications resulting in successful registration. Currently, 0 applications are pending review.